Across TCGA pan-cancer cohorts, CASP12 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CASP12 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CASP12 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CASP12 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, SKCM, and UCEC are the cancer types where CASP12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.149	0.687	.005	18	view →
SKCM	OS	Median	All	0.179	0.781	<.001	9	view →
UCEC	DFS	Median	II,III,IV	1.000	0.445	.037	8	view →
SCLC	OS	Median	II,III,IV	0.301	0.706	.020	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CASP12 tumor-vs-normal RNA expression · all CASP12 data types